Evaluation of the Quality of Life and Gynecological Follow-up of Patients Treated for Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome
Evaluation of the Overall Quality of Life and Gynecological Follow-up of Patients Treated for Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome at the Toulouse University Hospital
University Hospital, Toulouse
102 participants
Mar 4, 2026
OBSERVATIONAL
Conditions
Summary
Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome affects 1 in 4,500 women and consists of utero-vaginal aplasia in 46 chromosom XX women, most often diagnosed in the presence of primary amenorrhea. This diagnosis, occurring in adolescence during the period of identity formation, can have significant psychological repercussions. This malformation can alter the body image and personal relationships of affected patients, beyond the impact on their sexual lives. Management around the disclosure is a crucial moment for these patients. Individual or group psychological support is systematically offered. Several international studies show that these patients experience a decline in their quality of life, and they are more anxious and depressed. Participation in support groups improves this state. The objective of this study is therefore to better understand Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome and the issues patients may face. For this reason, it seems essential to us to evaluate the overall quality of life, the quality of sexual life, the psychological state and the gynecological follow-up of women before or after treatment for vaginal aplasia.
Eligibility
Inclusion Criteria11
- For Mayer-Rokitansky-Küster-Hauser patients:
- Patient over 18 and under 50
- Confirmed diagnosis of Mayer-Rokitansky-Küster-Hauser syndrome
- Diagnosis announced more than 1 year ago
- Patient treated by the CRMR PGR
- Patient affiliated with or benefiting from a social security scheme
- Fluency in French
- For the control population:
- Patient over 18 and under 50
- Patient affiliated with or benefiting from a social security scheme
- Fluency in French
Exclusion Criteria10
- For Mayer-Rokitansky-Küster-Hauser patients:
- Minors over 50 years of age
- Recent diagnosis < 1 year
- Other causes of uterine or vaginal aplasia, surgical or congenital
- Patients benefiting from a legal protection measure (guardianship, curatorship, legal protection)
- Patients unable to understand or answer the questionnaires
- For the control population:
- Minors over 50 years of age
- Patients benefiting from a legal protection measure (guardianship, curatorship, legal protection)
- Patients unable to understand or answer the questionnaires
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
questionnaires: WHOQOL-BREF (Quality of Life Study Questionnaire), FSFI (Female Sexual Function Index), FSDS-R (The Femala sexual distress scale-revised), Rosenberg scale (self-esteem assessment)
Semi-directed interview on the treatment pathway and the impact of utero-vaginal aplasia on intimate and personal life
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07186764